Julie Hejgaard Laursen1, Helle Bach Søndergaard2, Per Soelberg Sørensen2, Finn Sellebjerg2, Annette Bang Oturai2. 1. Rigshospitalet, Copenhagen University Hospital, Danish Multiple Sclerosis Center, Department of Neurology, Blegdamsvej 9, 2100 Copenhagen, Denmark. Electronic address: juliehejgaard@hotmail.com. 2. Rigshospitalet, Copenhagen University Hospital, Danish Multiple Sclerosis Center, Department of Neurology, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Abstract
BACKGROUND: Vitamin D insufficiency is common among multiple sclerosis patients, and hypovitaminosis D has been associated with multiple sclerosis (MS) risk and disease activity. OBJECTIVE: To investigate how recommendations on vitamin D3 supplements affect 25-hydroxyvitamin D (25(OH)D) levels in patients with relapsing-remitting MS (RRMS) and to examine the clinical effects associated with changes in 25(OH)D levels. METHODS: In this prospective cohort study, baseline blood samples were collected from 170 natalizumab-treated RRMS patients during winter 2009-2010 and were repeated the following winter. Vitamin D supplements were recommended according to standard clinical practice in our clinic to patients with serum 25(OH)D<50nmol/l at baseline. Information was obtained on annualized relapse-rate (ARR) the year prior to baseline and the following year. RESULTS: We found that recommending vitamin D supplements in patients with vitamin D insufficiency was associated with a significant increase in serum 25(OH)D concentrations (p=5.1×10-10), which was significantly related with decreases in ARR; for each nmol/l increase in Δ25(OH)D a -0.014 (95% CI -0.026 to -0.003) decrease in ΔARR was observed, p=0.02. CONCLUSION: Correction of hypovitaminosis D in clinical practice by recommending oral D3 supplements resulted in increases in 25(OH)D levels in serum, which were associated with decreases in ARR in RRMS. Copyright Â
BACKGROUND:Vitamin Dinsufficiency is common among multiple sclerosispatients, and hypovitaminosis D has been associated with multiple sclerosis (MS) risk and disease activity. OBJECTIVE: To investigate how recommendations on vitamin D3 supplements affect 25-hydroxyvitamin D (25(OH)D) levels in patients with relapsing-remitting MS (RRMS) and to examine the clinical effects associated with changes in 25(OH)D levels. METHODS: In this prospective cohort study, baseline blood samples were collected from 170 natalizumab-treated RRMS patients during winter 2009-2010 and were repeated the following winter. Vitamin D supplements were recommended according to standard clinical practice in our clinic to patients with serum 25(OH)D<50nmol/l at baseline. Information was obtained on annualized relapse-rate (ARR) the year prior to baseline and the following year. RESULTS: We found that recommending vitamin D supplements in patients with vitamin Dinsufficiency was associated with a significant increase in serum 25(OH)D concentrations (p=5.1×10-10), which was significantly related with decreases in ARR; for each nmol/l increase in Δ25(OH)D a -0.014 (95% CI -0.026 to -0.003) decrease in ΔARR was observed, p=0.02. CONCLUSION: Correction of hypovitaminosis D in clinical practice by recommending oral D3 supplements resulted in increases in 25(OH)D levels in serum, which were associated with decreases in ARR in RRMS. Copyright Â
Authors: Mark A Little; Lina Zgaga; Jennifer Scott; Enock Havyarimana; Albert Navarro-Gallinad; Arthur White; Jason Wyse; Jos van Geffen; Michiel van Weele; Antonia Buettner; Tamara Wanigasekera; Cathal Walsh; Louis Aslett; John D Kelleher; Julie Power; James Ng; Declan O'Sullivan; Lucy Hederman; Neil Basu Journal: Arthritis Res Ther Date: 2022-06-18 Impact factor: 5.606
Authors: Steve Simpson; Ingrid van der Mei; Robyn M Lucas; Anne-Louise Ponsonby; Simon Broadley; Leigh Blizzard; Bruce Taylor Journal: Front Neurol Date: 2018-02-01 Impact factor: 4.003
Authors: Ali Manouchehrinia; Anna Karin Hedström; Lars Alfredsson; Tomas Olsson; Jan Hillert; Ryan Ramanujam Journal: Front Neurol Date: 2018-05-11 Impact factor: 4.003